UK Markets open in 7 hrs 34 mins

BNTX Jan 2023 105.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
75.900.00 (0.00%)
As of 11:30AM EST. Market open.
Full screen
Previous close75.90
Open177.13
Bid59.90
Ask63.30
Strike105.00
Expiry date2023-01-20
Day's range75.90 - 75.90
Contract rangeN/A
Volume2
Open interest1
  • Business Wire

    Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

    NEW YORK & MAINZ, Germany, December 08, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age. Children in this age group can receive a primary series consisting of two 3-µg doses of the original Pfizer-BioNTech COVID-19 Vaccine

  • Zacks

    Pfizer (PFE) Seeks FDA Nod for Bivalent COVID Jab in Infants

    Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.

  • Reuters

    Pfizer, BioNTech countersue Moderna over COVID-19 vaccine patents

    (Reuters) -Pfizer Inc and its German partner, BioNTech SE, fired back at Moderna Inc on Monday in a patent lawsuit over their rival COVID-19 vaccines, seeking dismissal of the lawsuit in Boston federal court and an order that Moderna's patents are invalid and not infringed. Moderna first sued Pfizer in August, accusing the company of violating its rights in three patents related to innovations that Cambridge, Massachusetts-based Moderna said it pioneered before the COVID-19 pandemic. Moderna has also filed a related lawsuit against Pfizer and BioNTech in Germany.